New data indicate that its cell therapy could soon find a larger market. It's always a nice surprise to see that a company you're invested in is making good on its opportunities and planning to grow on your behalf. In that vein, at the 2024 meeting of the American Society of Clinical Oncology (ASCO) on May 31, Iovance Biotherapeutics (IOVA 0.58%) offered some news that should please its shareholders and perhaps motivate them to buy more of the stock in the near term. To appreciate what it disclosed and why ...